Phase I, Open-Label, Multi-Center, Accelerated Dose Escalation Study Of The Anti-Angiogenesis Agent PF-00337210 In Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 01 Mar 2016
At a glance
- Drugs PF 337210 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 18 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Aug 2011 Planned End Date changed from 1 Jun 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.